logo

Preparation and preliminary evaluation of [55Co](II)vancomycin

RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE

Preparation and preliminary evaluation of [55Co](II)vancomycin

Amir Reza JALILIAN
Yousef YARI-KAMRANI
Pejman ROWSHANFARZAD
Mahseed SABET
Mohsen KAMALI-DEHGHAN
Abbas MAJDABADI
Nuclear Science and TechniquesVol.19, No.6pp.347-353Published in print 20 Dec 2008
33200

Co-55 (t1/2=17.53 h) was produced by 150 μA irradiation of a natural nickel target using 15 MeV protons. It was separated from the irradiated target material by two ion exchange chromatography steps with a radiochemical yield of >95% and was used for the preparation of [55Co]vancomycin ([55Co]VAN). Optimization studies were performed using Co-57 due to its longer half-life. Cobalt-57 (t1/2=271.79 d) was produced by irradiation of a natural nickel target with 150 μA current of 22 MeV protons. The 57Co was separated from the irradiated target material using a no-carrier-added method with a radiochemical yield of >97%. Both products were controlled for radionuclide and chemical purity. The solutions of [55Co]VAN were prepared (radiochemical yield>80%) starting with 55Co acetate and vancomycin at room temperature after 30 min. A precise solid phrase extraction (SPE) method was developed using Si Sep-Pak in order to purify/reconstitute the final formulation for animal studies. [55Co]VAN showed a radiochemical purity of more than 99%. The resultant specific activity was about 1.15 TBq/mmol. It is proved that the tracer is stable in the final product and in presence of human serum at 37°C up to 24 h. Biodistribution study of [55Co]VAN in normal rats was undertaken for up to 72 h.

Cobalt-55VancomycinMedical cyclotronRadiolabelingBiodistribution
References
[1] Even-Sapir E, Bettman L, Iosilevsky G, et al. J Nucl Med, 1994, 35(7): 1129-1133.
[2] Beck R A, Anes J M, Savini L M, et al. J Chromatogr A, 2000, 881(1-2): 345-356.
[3] Van de Wiele C, Goethals P, Volkaert A, et al. Nucl Med Commun, 2000, 21(4): 313-316.
[4] Smith T A. Bioorg Med Chem, 2005, 13(14): 4576-4579.
[5] De Reuck J, Paemeleire K, Santens P, et al. Clin Neurol Neurosurg, 2004, 106: 77-81.
[6] De Reuck J, Santens P, Strijckmans K, et al. J Neurolog Sci, 2001, 193: 1-6.
[7] Goethals P, Volkaert A, Vandewielle C, et al. Nucl Med Biol, 2000, 27: 77-81.
[8] Stevens H, Jansen H M L, De Reuck J, et al. J Neurolog Sci, 1999, 171: 11-18.
[9] Britton K E, Vinjamuri S, Hall A V, et al. Eur J Nucl Med, 1997, 24: 553-556.
[10] Calame W, Welling M, Feitsma H I, et al. Eur J Nucl Med, 1993, 20: 490-494.
[11] Knight L C. Q J Nucl Med, 2003, 47(4):279-291.
[12] Vancomycin Injection (Vancomycin HCl). Abbot Laboratories (Pakistan) Ltd. Landhi, Karachi (1976).
[13]

Antibiotic-metal complexes in the detection of gram-positive bacteria and other biological analytes

, Document Type and Number: United States Patent 20050026813, Kind Code:A1
Baidu ScholarGoogle Scholar
[14] Roohi S, Mushtaq M, Malik S A. Radiochim Acta, 2005, 93: 415-418.
[15] Jalilian A R, Hosseini M A, Saddadi F, et al. Nukleonika, 2006, 51(4): 203-208.
[16] Vancomycin Injection (Vancomycin HCl). Eli Lilly and Company, Lilly Corporate Center Indianapolis, IN, (2004).
[17] Ziegler J F, Biersack J P, Littmark U. The stopping and range of ions in matter (SRIM Code). Version 2000 XX (2000).
[18] Jalilian A R, Mirsadeghi L, Yari-kamrani Y, et al. J Radioanal Nucl Chem, 2007, 274(3): 563-568.
[19] Jalilian A R, Sabet M, Rowshanfarzad P, et al. J Radioanal Nucl Chem, 2006, 269(1): 147-154.
[20] Moore G E, Kraus K A. J Am Chem Soc, 1962, 74: 843-844.
[21] Sharma H, Zweit J, Smith A M, et al. Int J Appl Radiat Isot, 1986, 37(2): 105-109.
[22] Hou X, Jacobsen U, Jorgensen J C. Appl Radiat Isot, 2002, 57(6): 773-777.
[23] Marczenko Z. Spectrophotometric determination of elements. Chichester: Ellis Horwood Ltd., 1976: 369-371.
[24] Marczenko Z. Spectrophotometric determination of elements. Chichester: Ellis Horwood Ltd., 1976: 281-284.
[25] Marczenko Z. Spectrophotometric determination of elements. Chichester: Ellis Horwood Ltd., 1976: 211-218.
[26] Agency for Toxic Substances and Disease Registry, ATSDR/U.S. Public Health Service, Toxicological Profile for Nickel, (ATSDR)/TP-88/19, 1988.
[27] Vancomycin Injection (Vancomycin HCl). Eli Lilly and Company, Lilly Corporate Center Indianapolis, IN, (2004).
[28] http://www.rxlist.com/cgi/generic2/vancomycin_cp.htm.